Why the study?
Does percutaneous intramyocardial skeletal myoblast injection improve long-term LV function in patients with ischaemic cardiomyopathy?
Does percutaneous intramyocardial skeletal myoblast injection improve long-term LV function in patients with ischaemic cardiomyopathy?
Percutaneous intramyocardial skeletal myoblast injection does not provide sustained improvement in LV function at 4 years in ischemic cardiomyopathy and may increase the risk of serious arrhythmias.
No takes yet. Share an insight, caveat, or question.
No sustained LVEF benefit with skeletal myoblast injection in this cohort; hypothesis-generating and should not change practice pending RCTs.
Veltman et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: